# Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

> **NCT01861912** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 258 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DEVICE:** Arsenic trioxide TACE
- **DRUG:** Arsenic trioxide intravenous infusion
- **DRUG:** lipiodol
- **DRUG:** NaCl solution

## Key facts

- **NCT ID:** NCT01861912
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01861912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01861912, "Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01861912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*